Sign in

ENDP on NASDAQ

Endo International plc

Ireland-domiciled pharmaceutical company

Endo International plc is an American Irish-domiciled generics and specialty branded pharmaceutical company that generated over 93% of its 2017 sales from the U.S. healthcare system. While Endo's management, operations, and customers are almost exclusively U.S.–based, in 2013 Endo executed a corporate tax inversion to Ireland to avoid U.S. corporate taxes on their U.S. drug sales, and to avail of Ireland's corporate tax system.3 Its shares trade on NASDAQ under the symbol ENDP.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1997Founded1

Compare with Sarepta Therapeutics, PTC Therapeutics or Royalty Pharma plc, or pick any stock.

  • TickerENDP on NASDAQ1
  • Industrypharmaceutical industry1
  • HeadquartersIreland1
  • Websitewww.endo.com
  • Legal formpublic limited company1
  • Business addressMinerva House, Simmonscourt Road, Ballsbridge, Dublin 4, L2 000004
  • Filer categoryNon-accelerated filer, Smaller reporting company4

See how the biggest companies compare on our leaderboards

Endo International plc is an American Irish-domiciled generics and specialty branded pharmaceutical company that generated over 93% of its 2017 sales from the U.S. healthcare system. While Endo's management, operations, and customers are almost exclusively U.S.–based, in 2013 Endo executed a corporate tax inversion to Ireland to avoid U.S. corporate taxes on their U.S. drug sales, and to avail of Ireland's corporate tax system.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-121.8%Net margin7
-13.3%Revenue growth, 20237
$340.8MFree cash flow7

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Cost of revenue47¢$946.4M
  • Selling, general and admin28¢$567.7M
  • Other costs22¢$441.5M
  • Income tax3¢$55.9M

Out of $2.0B in revenue.7 The company lost money this year.

Where each dollar of operating cash went, fiscal 2023

  • Capital spending22¢$94.3M
  • Kept or used elsewhere78¢$340.8M

Out of $435.1M of cash from operations.7

Financial statements

Revenue8910117$2.0B in 2023−42% since 2017
0$1.0B$2.0B$3.0B$4.0B2017: $3.5B$3.5B20172018: $2.9B$2.9B2018−15%2019: $2.9B$2.9B2019−1%2020: $2.9B$2.9B2020−0%2021: $3.0B$3.0B2021+3%2022: $2.3B$2.3B2022−23%2023: $2.0B$2.0B2023−13%
Operating income12-$469.1M in 2018−51% since 2017
-$1.0B-$750.0M-$500.0M-$250.0M02017: -$960.1M-$960.1M20172018: -$469.1M-$469.1M2018−51%
Net income8910117-$2.4B in 2023+20% since 2017
-$3.0B-$2.0B-$1.0B0$1.0B2017: -$2.0B-$2.0B20172018: -$1.0B-$1.0B2018−49%2019: -$422.6M-$422.6M2019−59%2020: $183.9M$183.9M20202021: -$613.2M-$613.2M20212022: -$2.9B-$2.9B2022+377%2023: -$2.4B-$2.4B2023−16%
Fiscal year2017201820192020202120222023
Revenue$3.5B8$2.9B9$2.9B10$2.9B11$3.0B7$2.3B7$2.0B7
Cost of revenue$2.2B8$1.6B9$1.6B10$1.4B11$1.2B7$1.1B7$946.4M7
Research and development$172.1M8$185.8M9$130.7M10$158.9M10$148.6M10
Selling, general and admin$629.9M8$646.0M9$632.4M10$698.5M11$861.8M7$777.2M7$567.7M7
Operating income-$960.1M12-$469.1M12
Interest$521.7M9$538.7M10$532.9M11$562.4M7$349.8M7$07
Income before tax-$546.6M7-$2.9B7-$2.4B7
Income tax-$250.3M8$22.9M9$15.7M10-$274.0M11$22.5M7$21.5M7$55.9M7
Net income-$2.0B8-$1.0B9-$422.6M10$183.9M11-$613.2M7-$2.9B7-$2.4B7
Earnings per share-$9.128-$4.619-$1.8710$0.8011-$2.637-$12.457-$10.427
Earnings per share (diluted)-$9.128-$4.619-$1.8710$0.7911-$2.637-$12.457-$10.427
Shares (weighted, basic)232.8M shares7234.8M shares7235.2M shares7
Shares (weighted, diluted)232.8M shares7234.8M shares7235.2M shares7

Compare Endo International plc with another company

Corporate structure

Endo International plc sits at the top of its group. 88 entities, 7 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Endo International plc

  • Endo International plc Ireland
    • Paladin Labs (Canada) Subsidiary · Montreal West, Canada
    • 70 Maple Avenue, LLC Subsidiary · Delaware, United States
    • Actient Pharmaceuticals LLC Subsidiary · Delaware, United States
    • Actient Therapeutics, LLC Subsidiary · Delaware, United States
    • Anchen Incorporated Subsidiary · New York, United States
    • Anchen Pharmaceuticals, Inc. Subsidiary · Delaware, United States
    • Astora Women's Health Bermuda ULC Subsidiary · Bermuda
    • Astora Women's Health Ireland Limited Subsidiary · Ireland
    • Astora Women's Health Technologies Subsidiary · Ireland
    • Astora Women's Health, LLC Subsidiary · Delaware, United States
    • Auxilium International Holdings, LLC Subsidiary · Delaware, United States
    • Auxilium Pharmaceuticals, LLC Subsidiary · Delaware, United States
    • Auxilium US Holdings, LLC Subsidiary · Delaware, United States
    • Bermuda Acquisition Management Limited Subsidiary · Bermuda
    • BioSpecifics Technologies LLC Subsidiary · Delaware, United States
    • Branded Operations Holdings, Inc. Subsidiary · Delaware, United States
    • CPEC LLC Subsidiary · Delaware, United States
    • DAVA International, LLC Subsidiary · Delaware, United States
    • DAVA Pharmaceuticals, LLC Subsidiary · Delaware, United States
    • Endo Aesthetics LLC Subsidiary · Delaware, United States
    • Endo Bermuda Finance Limited Subsidiary · Bermuda
    • Endo Designated Activity Company Subsidiary · Ireland
    • Endo Eurofin Unlimited Company Subsidiary · Ireland
    • Endo Finance IV Unlimited Company Subsidiary · Ireland
    • Endo Finance LLC Subsidiary · Delaware, United States
    • and 62 more

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Endo International plc reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Finance-lease assets$18.7M7 Dec 31, 2023$26.8M7 Dec 31, 2022−30.2%
Operating-lease assets (leased space)$23.0M7 Dec 31, 2023$28.1M7 Dec 31, 2022−17.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$777.9M7 Dec 31, 2023$1.0B7 Dec 31, 2022−23.6%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$1.4B7 Dec 31, 2023$1.4B7 Dec 31, 20220%
Intangible assets, net (excluding goodwill)$1.5B7 Dec 31, 2023$1.7B7 Dec 31, 2022−14.7%
Finite-lived intangibles, gross$6.4B7 Dec 31, 2023$6.4B7 Dec 31, 2022−0.1%
Accumulated amortization$4.9B7 Dec 31, 2023$4.6B7 Dec 31, 2022+5.4%

Inventory

ItemLatestA year beforeChange
Inventory, total$246.0M7 Dec 31, 2023$274.5M7 Dec 31, 2022−10.4%
Raw materials$103.3M7 Dec 31, 2023$106.0M7 Dec 31, 2022−2.5%
Work in process$29.8M7 Dec 31, 2023$43.1M7 Dec 31, 2022−30.7%
Finished goods$112.9M7 Dec 31, 2023$125.5M7 Dec 31, 2022−10.1%

The story

In 1920, Intravenous Products of America was incorporated as a privately owned pharmaceutical business operating in New York. By 1935 it had changed its name to Endo Products. The product line focused on medication for the treatment of pain (e.g. Percodan), a focus which continued during its acquisition by DuPont in 1969 (e.g. Percocet).

Endo Pharmaceuticals Holdings was created as a result of a $277 million management buyout of the division from DuPont Merck in 1997, led by Carol Ammon. Through the merger with Algos, it changed name again to Endo Pharmaceuticals Holdings Inc. and began trading as a public company.

In 2012, shareholders voted to again change the name to Endo Health Solutions, with Endo Pharmaceuticals becoming a segment of the business. Through the 2014 acquisition of Paladin Labs and subsequent corporate restructuring, Endo International plc was formed.

2022–2023 bankruptcy proceedings

In 2022, Endo's stock fell below $1 as the company faced restructuring of its $8 billion of debt.

On August 17, 2022 Endo International Plc filed for Chapter 11 bankruptcy protection after reaching a $6 billion deal with some of its creditors that related to opioid litigation in the US and a $6 billion deal with creditors, including for settling lawsuits.

The United States Department of Justice has objected to the plans, claiming they violate bankruptcy law.

Merger

In March 2025, Mallinckrodt and Endo announced plans to merge in a deal valued at $6.7 billion.

From Wikipedia’s article on Endo International, shared under CC BY-SA 4.0.5

Leadership

Who has led Endo International plc, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Silva Rajiv De2014–2016
  2. Paul Campanelli2016–2020
  3. Blaise Coleman2020–2022

President

  1. Camille Farhat2014–2015
  2. Silva Rajiv De2014–2016
  3. Brian Lortie2015–2016
  4. Paul Campanelli2015–2020
  5. Joseph Ciaffoni2016
  6. Antonio R. Pera2016–2019
  7. Blaise Coleman2020–2022

Chief financial officer

  1. Suketu Upadhyay2014–2016
  2. Blaise Coleman2016–2020
  3. Mark T. Bradley2020–2022

Chief operating officer

  1. Donald W. Degolyer2014–2015
  2. Terrance J. Coughlin2016–2020
200020052010201520202025
Board members and other officers (29)

Subsidiaries and ownership

Subsidiaries

Subsidiaries (Exhibit 21)

  • 70 Maple Avenue, LLC Delaware6
  • Actient Pharmaceuticals LLC Delaware6
  • Actient Therapeutics, LLC Delaware6
  • Anchen Incorporated New York6
  • Anchen Pharmaceuticals, Inc. Delaware6
  • Astora Women's Health Bermuda ULC Bermuda6
  • Astora Women's Health Ireland Limited Ireland6
  • Astora Women's Health Technologies Ireland6
  • Astora Women's Health, LLC Delaware6
  • Auxilium International Holdings, LLC Delaware6
  • Auxilium Pharmaceuticals, LLC Delaware6
  • Auxilium US Holdings, LLC Delaware6
  • Bermuda Acquisition Management Limited Bermuda6
  • BioSpecifics Technologies LLC Delaware6
  • Branded Operations Holdings, Inc. Delaware6
  • CPEC LLC Delaware6
  • DAVA International, LLC Delaware6
  • DAVA Pharmaceuticals, LLC Delaware6
  • Endo Aesthetics LLC Delaware6
  • Endo Bermuda Finance Limited Bermuda6
  • Endo Designated Activity Company Ireland6
  • Endo Eurofin Unlimited Company Ireland6
  • Endo Finance IV Unlimited Company Ireland6
  • Endo Finance LLC Delaware6
All 86 listed subsidiaries
  • Endo Finance Operations LLC Delaware6
  • Endo Finco Inc. Delaware6
  • Endo Generics Holdings, Inc. Delaware6
  • Endo Global Aesthetics Limited Ireland6
  • Endo Global Biologics Unlimited Company Ireland6
  • Endo Global Development Limited Ireland6
  • Endo Global Finance LLC Delaware6
  • Endo Global Ventures Bermuda6
  • Endo Health Solutions Inc. Delaware6
  • Endo India Holdings, LLC Delaware6
  • Endo Innovation Valera, LLC New York6
  • Endo Ireland Finance II Limited Ireland6
  • Endo LLC Delaware6
  • Endo Luxembourg Finance Company I S.a r.l. Luxembourg6
  • Endo Luxembourg Holding Company S.a r.l. Luxembourg6
  • Endo Luxembourg International Financing S.a r.l. Luxembourg6
  • Endo Management Limited Ireland6
  • Endo Par Innovation Company, LLC Delaware6
  • Endo Pharmaceuticals Finance LLC Delaware6
  • Endo Pharmaceuticals Inc. Delaware6
  • Endo Pharmaceuticals Solutions Inc. Delaware6
  • Endo Pharmaceuticals Valera Inc. Delaware6
  • Endo Procurement Operations Limited Ireland6
  • Endo TopFin Limited Ireland6
  • Endo U.S. Inc. Delaware6
  • Endo US Holdings Luxembourg I S.a r.l. Luxembourg6
  • Endo Ventures Aesthetics Limited Ireland6
  • Endo Ventures Bermuda Limited Bermuda6
  • Endo Ventures Unlimited Company Ireland6
  • Generics Bidco I, LLC Delaware6
  • Generics International (US) 2, Inc. Delaware6
  • Generics International (US), Inc. New York6
  • Generics International Ventures Enterprises LLC Pennsylvania6
  • Hawk Acquisition Ireland Limited Ireland6
  • Innoteq, Inc. Delaware6
  • JHP Acquisition, LLC Delaware6
  • JHP Group Holdings, LLC Delaware6
  • Kali Laboratories 2, Inc. Delaware6
  • Kali Laboratories, LLC New Jersey6
  • Luxembourg Endo Specialty Pharmaceuticals Holding I S.a r.l. Luxembourg6
  • Moores Mill Properties L.L.C. Delaware6
  • Operand Pharmaceuticals Holdco I Limited Ireland6
  • Operand Pharmaceuticals Holdco II Limited Ireland6
  • Operand Pharmaceuticals Holdco III Limited Ireland6
  • Operand Pharmaceuticals II Limited Ireland6
  • Operand Pharmaceuticals III Limited Ireland6
  • Paladin Labs Canadian Holding Inc. Canada6
  • Paladin Labs Inc. Canada6
  • Par Active Technologies Private Limited India6
  • Par Biosciences Private Limited India6
  • Par Formulations Private Limited India6
  • Par Laboratories Europe, Ltd. England and Wales6
  • Par Pharmaceutical 2, Inc. Delaware6
  • Par Pharmaceutical Companies, Inc. Delaware6
  • Par Pharmaceutical Holdings, Inc. Delaware6
  • Par Pharmaceutical, Inc. New York6
  • Par Sterile Products, LLC Delaware6
  • Par, LLC Delaware6
  • Quartz Specialty Pharmaceuticals, LLC Delaware6
  • Slate Pharmaceuticals, LLC Delaware6
  • Timm Medical Holdings, LLC Delaware6
  • Vintage Pharmaceuticals, LLC Delaware6

From Wikidata.1 The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Acquisitions

1999: Predecessor Endo Pharmaceuticals Holdings agreed to buy Algos Pharmaceutical Corporation, in a bid to gain additional products for the painkiller market.

2006: Endo acquired RxKinetix, leading to a fall in profits.

2009: Endo bought Indevus Pharmaceuticals to diversify into endocrinology and oncology. The company entered the male hypogonadism market later in 2010 with Fortesta 2% gel.

2010: Endo acquired generic manufacturer Qualitest Pharmaceuticals for $1.2 billion.

Read the full text

2011: Endo acquired medical device manufacturer American Medical Systems for more than $2 billion

2013: Endo agreed to purchase Paladin Labs Inc for about $1.6 billion to gain access to the Canadian market as well as expand into emerging markets. The acquisition was subsequently used via Canadian tax laws to execute a corporate tax inversion to Ireland. In July 2015, The Wall Street Journal noted Endo was using Ireland's lower tax rate to acquire U.S.–based life sciences firms and relocate them to Ireland's tax regime (i.e. they could afford to pay more to acquire U.S. competitors).

2014: In early 2014, Endo sought to acquire NuPathe, a speciality pharmaceutical developer, for $105 million. However, Teva prevailed in this acquisition with a substantially higher bid. In September 2014, Endo offered to buy Auxilium Pharmaceuticals and its portfolio in a then rejected offer, before acquiring the company the following month in a deal valued at $2.6 billion. This expanded Endo's portfolio to include 12 additional products, including a variery of testosterone preparations, and Xiaflex (a treatment for Peyronie's disease). In the same year, they also acquired Dava Pharmaceuticals.

2015: Endo acquired the specialty generics and sterile injectables company Par Pharmaceutical for $8.05 billion. The FTC required divestments of assets to Rising Pharmaceuticals for the deal to go through.

2018-19: Endo announced and then terminated a deal to acquire Somerset Therapeutics.

2020: Endo acquired BioSpecifics Technologies for more than $500 million.

From Wikipedia’s article on Endo International, shared under CC BY-SA 4.0.5

Former names

  • Endo International LtdDec 11, 2013 to Jan 27, 20144

Timeline

  1. Apr 18, 20248-K Entered a material agreement; Bankruptcy or receivership55
  2. Mar 25, 20248-K Bankruptcy or receivership; Other events56
  3. Mar 6, 20248-K Results of operations57
  4. Jan 2, 20248-K Entered a material agreement; Regulation FD disclosure58
  5. Dec 29, 20238-K Other events59
  6. Dec 26, 20238-K Regulation FD disclosure60
  7. Nov 30, 20238-K Other events61
  8. Nov 6, 20238-K Results of operations; Regulation FD disclosure62
  9. Oct 2, 20238-K Other events63
  10. Sep 8, 20238-K Executive or director change; Shareholder vote64
  11. Sep 1, 20238-K Other events65
  12. Aug 15, 20238-K Other events66
  13. Mar 31, 2020New chief executive Blaise Coleman becomes CEO16
  14. Sep 28, 2016New chief executive Paul Campanelli becomes CEO17
  15. Mar 4, 2014New chief executive Silva Rajiv De becomes CEO18
  16. 1997Founded Founded1

Calendar

When it reported results

  1. Mar 6, 2024Reported quarterly or annual results57
  2. Nov 6, 2023Reported quarterly or annual results62
  3. Aug 8, 2023Reported quarterly or annual results67
  4. May 8, 2023Reported quarterly or annual results68
  5. Mar 6, 2023Reported quarterly or annual results69
  6. Nov 9, 2022Reported quarterly or annual results70
  7. Aug 9, 2022Reported quarterly or annual results71
  8. May 5, 2022Reported quarterly or annual results72

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

90 filings to the SEC since October 2021: 4 annual reports, 7 quarterly reports, 45 major events, 12 insider forms, 11 large holders, 11 other. The latest 20:

  1. Feb 14, 2025SCHEDULE 13G EDGAR
  2. Apr 18, 20248-K EDGAR
  3. Mar 25, 20248-K EDGAR
  4. Mar 6, 202410-K EDGAR
  5. Mar 6, 20248-K EDGAR
  6. Jan 2, 20248-K EDGAR
  7. Dec 29, 20238-K EDGAR
  8. Dec 26, 20238-K EDGAR
  9. Nov 30, 20238-K EDGAR
  10. Nov 6, 202310-Q EDGAR
  11. Nov 6, 20238-K EDGAR
  12. Oct 2, 20238-K EDGAR
  13. Sep 8, 20238-K EDGAR
  14. Sep 1, 20238-K EDGAR
  15. Aug 15, 20238-K EDGAR
  16. Aug 8, 202310-Q EDGAR
  17. Aug 8, 20238-K EDGAR
  18. Jun 29, 20238-K EDGAR
  19. May 30, 20238-K EDGAR
  20. May 8, 202310-Q EDGAR

The 90 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Endo International plc is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAREndo International plc2
  • CIK0001593034
  • Employer ID (EIN)68-06837552
  • Filer statusNon-accelerated filer<br>smaller reporting company2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business addressMinerva House, Simmonscourt Road, Ballsbridge, Dublin 4, L2 000002
  • Phone353-1-268-20002
  • Shares outstanding235,219,612 as of Feb 28, 20247
  • Public float$4.1M as of Jun 30, 20237
  • On EDGAR sinceDec 11, 20132
  • Filings819 in all: 4 (346), 8-K (207), 3 (40), SC 13G/A (37), 10-Q (30), 425 (26), SC 13G (18), DEFA14A (15)2
    All 42 form types

    10-K (10), DEF 14A (9), NO ACT (8), CT ORDER (7), 8-K/A (6), S-8 (6), S-8 POS (6), 4/A (4), S-3ASR (3), SC TO-T/A (3), SD (3), 3/A (2), 424B3 (2), 424B5 (2), 424B7 (2), EFFECT (2), PRE 14A (2), S-4 (2), S-4/A (2), SC 13D (2), SC 13D/A (2), SC TO-C (2), UPLOAD (2), 10-K/A (1), 10-Q/A (1), 15-12G (1), 25-NSE (1), 5 (1), 8-K12B (1), CORRESP (1), DEFR14A (1), POSASR (1), SC TO-T (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Mar 6, 2024
    Quarterly report (10-Q) Nov 6, 2023
    Proxy statement (DEF 14A) Apr 28, 2022
    Latest 8-K (8-K) Apr 18, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
    SEC EDGAROther events
  60. 60
  61. 61
    SEC EDGAROther events
  62. 62
  63. 63
    SEC EDGAROther events
  64. 64
  65. 65
    SEC EDGAROther events
  66. 66
    SEC EDGAROther events
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78